Browse > Article

Natural Iminosugar Derivatives of 1-Deoxynojirimycin Inhibit Glycosylation of Hepatitis Viral Envelope Proteins  

Jacob, James R. (Department of Clinical Sciences, College of Veterinary Medicine, Cornell University)
Mansfield, Keith (Division of Primate Resources, New England Regional Primate Research Center, Harvard Medical School)
You, Jung-Eun (Department of Life Sciences, The University of Suwon)
Tennant, Bud C. (Department of Clinical Sciences, College of Veterinary Medicine, Cornell University)
Kim, Young-Ho (Department of Life Sciences, The University of Suwon)
Publication Information
Journal of Microbiology / v.45, no.5, 2007 , pp. 431-440 More about this Journal
Abstract
A silkworm (Bombyx mori L.) extract known to contain naturally occurring iminosugars, including 1-deoxynojirimycin (1-DNJ) derived from the mulberry tree (Morus alba L.), was evaluated in surrogate HCV and HBV in vitro assays. Antiviral activity of the silkworm extract and one of its purified constituents, 1-DNJ, was demonstrated against bovine viral diarrhea virus (BVDV) and GB virus-B (GBV-B), both members of the Flaviviridae family, and against woodchuck hepatitis virus (WHV) and hepatitis B virus (HBV), both members of the Hepadnaviridae family of viruses. The silkworm extract exhibited a 1,300 fold greater antiviral effect against BVDV in comparison to purified 1-DNJ. Glycoprotein processing of BVDV envelope proteins was disrupted upon treatment with the naturally derived components. The glycosylation of the WHV envelope proteins was affected largely by treatment with the silkworm extract than with purified 1-DNJ as well. The mechanism of action for this therapy may lie in the generation of defective particles that are unable to initiate the next cycle of infection as demonstrated by inhibition of GBV-B in vitro. We postulate that the five constituent iminosugars present in the silkworm extract contribute, in a synergistic manner, toward the antiviral effects observed for the inhibition of intact maturation of hepatitis viral particles and may complement conventional therapies. These results indicate that pre-clinical testing of the natural silkworm extract with regards to the efficacy of treatment against viral hepatitis infections can be evaluated in the respective animal models, in preparation for clinical trials in humans.
Keywords
silkworm; iminosugar; 1-deoxynojirimycin; hepatitis virus; glycosylation inhibition;
Citations & Related Records

Times Cited By Web Of Science : 5  (Related Records In Web of Science)
Times Cited By SCOPUS : 6
연도 인용수 순위
1 Corapi, W.V., R.O. Donis, and E.J. Dubovi. 1990. Characterization of a panel of monoclonal antibodies and their use in the study of the antigenic diversity of bovine viral diarrhea virus. Am. J. Vet. Res. 51, 1388-1394   PUBMED
2 Hoofnagle, J.H. and A.M. Di Bisceglie. 1997. The treatment of chronic viral hepatitis. New Engl. J. Med. 336, 337-356   DOI   ScienceOn
3 Kimura, M., F.J. Chen, N. Nakashima, I. Kimura, N. Asano, and S. Koya. 1995. Antihyperglycemic effects of N-containing sugars derived from Mulberry leaves in streptozocin-induced diabetic mice. J. Trad. Med. 12, 214-219
4 Liaw, Y.F. 2001. Concurrent hepatitis B and C virus infection: is hepatitis C virus stronger? J. Gastroenterol. Hepatol. 16, 597-598   DOI   ScienceOn
5 Liu, J., L. Kjaergard, and C. Glund. 2002. Misuse of randomization: a review of Chinese randomized trials of herbal medicines for chronic hepatitis B. Amer. J. Chinese Med. 30, 173-176   DOI   ScienceOn
6 Martin, K.W. and E. Ernest. 2003. Antiviral agents from plants and herbs; a systemic review. Antivir. Ther. 8, 77-90   PUBMED
7 Pestka, S. 1986. Interferon standards and general abbreviations. Meth. Enzymol. 119, 14-23   DOI
8 Strader, D.B. and H.J. Zimmerman. 2000. Complementary and alternative medicine in Hepatitis C, p. 363-386. In T.J. Liang and J.H. Hoofnagle (ed.), Biomedical Research Reports; Hepatitis C. Academic Press, New York, NY, USA
9 Asano, N. 2003. Glycosidase inhibitors: update and perspectives on practical use. Glycobiology 13, 93R-104R   DOI   PUBMED   ScienceOn
10 Branza-Nichita, N., D. Durantel, S. Carrouee-Durantel, R.A. Dwek, and N. Zitzmann. 2001. Antiviral effects of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers. J. Virol. 75, 3527-3536   DOI   ScienceOn
11 Schuppan, D., J.D. Jia, B. Brinhaus, and E.G. Hann, 1999. Herbal products for liver diseases: A therapeutic challenge for the new millennium. Hepatology 30, 1099-1104   DOI
12 Joubert, P.H., C.P. Venter, H.F. Joubert, and I. Hillebrand. 1985. The effect of 1-deoxynojirimycin derivative on post-pradial blood glucose and insulin levels in healthy black and white volunteers. Eur. J. Clin. Pharmacol. 28, 705-708   DOI
13 Tsiang, M., J.F. Roonex, J.J. Toole, and G.S. Gibbs. 1999. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 29, 1863-1869   DOI
14 Asano, N., K. Oseki, H. Kizu, and K. Matsui. 1994. Nitrogen-inthe- ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J. Med. Chem. 37, 3701-3706   DOI   ScienceOn
15 Chou, T.C. and P. Talalay. 1984. Quantitative Analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Reg. 22, 27-55   DOI   ScienceOn
16 Lanford, R.E., D. Chavez, B. Guerra, J.Y.N. Lau, Z. Hong, K.M. Brasky, and B. Beames. 2001. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 75, 8074-8081   DOI
17 Vilcek, J. and G.C. Sen. 1996. Interferons and other cytokines, p. 375-399. In B.N. Fields, D.M. Knipe, and P.M. Howley (ed.), Fields Virology. Lippincott-Raven Publishers, Philadelphia, PA, USA
18 Crespo, J., J.L. Lozano, B. Carte, B. De Las Heras, F. De La Cruz, and F. Pons-Romero. 1997. Viral replication in patients with concomitant hepatitis B and C virus infections. Eur. J. Clin. Infect. Dis. 16, 445-451   DOI   ScienceOn
19 Khakoo, S., P.G. Glue, L. Grellier, B. Wells, A. Bell, C. Dash, I. Murray-Lyon, D. Lypnyj, B. Flannery, K. Walters, and G.M. Dusheiko. 1998. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br. J. Clin. Pharmacol. 46, 563-570   DOI
20 Mehta, A., B. Conyers, D.L.J. Tyrrell, K.A. Walters, G.A. Tipples, R. Dwek, and T.M. Block. 2002. Structure-activity relationship of a new class of anti-hepatitis B virus agents. Antimicro. Agents Chemo. 46, 4004-4008   DOI
21 Stephensen, C.B., J.R. Jacob, R.J. Montali, R.J. Montali, E.D. Armes, M.J. Buchmeler, E. Muchmore, K.V. Holmes, and R.E. Lanford. 1991. Isolation of an arenavirus from a marmoset with callitrichid hepatitis and its serologic association with disease. J. Virol. 65, 3995-4000   PUBMED
22 Asano, N., T. Yamashita, K. Yasuda, K. Ikeda, H. Kizu, Y. Kameda, A. Kato, R.J. Nash, H.S. Lee, and K.S. Ryu. 2001. Polyhydroxylated alkaloids isolated from Mulberry trees (Morus alba L.) and silkworms (Bombyx mori L.). J. Agric. Food Chem. 49, 4208-4213   DOI   ScienceOn
23 Dobrinski, I., J.R. Jacob, B.C. Tennant, and B. Ball. 1999. Generation of an equine oviductal epithelial cell line for the study of sperm-oviduct interaction. Theriogenology 52, 875-885   DOI   ScienceOn
24 Zitzmann, N., A.S. Mehta, S. Carrouee, T.D. Butters, F.M. Platt, J. McCauley, B.S. Blumberg, R.A. Dwek, and T.M. Block. 1999. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl. Acad. Sci. USA 96, 11878-11882
25 Korba, B.E. and J.L. Gerin. 1992. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 19, 55-70   DOI   ScienceOn
26 Liang, T.J. 1999. Complementary and alternative medicine: The roots of healing. Gastroenterology 117, 1041   DOI   PUBMED   ScienceOn
27 Schvarcz, R., Z.B. Yun, A. Sonnerborg, and O. Weiland. 1995. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J. Med. Virol. 46, 43-47   DOI   ScienceOn
28 Asano, N., K. Oseki, E. Tomioka, H. Kizu, and K. Matsui. 1994. N-containing sugars from Morus alba and their glycosidase inhibitory activities. Carbohydr. Res. 259, 243-255   DOI   ScienceOn
29 Beames, B., D. Chavez, B. Guerra, L. Notvall, K.M. Brasky, and R.E. Lanford. 2000. Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus. J. Virol. 74, 11764-11772   DOI
30 Jacob, G.S. 1995. Gylcosylation inhibitors in biology and medicine. Curr. Opin. Struct. Bool. 5, 605-611   DOI   ScienceOn
31 Chisari, F.V. and C. Ferrari. 1997. Viral hepatitis, p. 745-778. In N. Nathanson (ed.), Viral pathogenesis. Lippincott-Raven Publishers, Philadelphia, PA, USA
32 Lu, X., A. Mehta, R. Dwek, T. Butters, and T. Block. 1995. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. Virol. 213, 660-665   DOI   ScienceOn
33 Tolle, T.K., D. Glebe, M. Linder, D. Linder, S. Schmitt, R. Geyer, and W.H. Gerlich. 1998. Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. J. Virol. 72, 9978-9985   PUBMED
34 Jacob, J.R., I. Toshkov, B.E. Korba, P.J. Cote, W. DeLaney, J.L. Gerin, and B.C. Tennant. 2004. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antiviral Res. In press
35 Ouzounzov, S., A.D. Menta, T.M. Block, and R. Jordan. 2002. The combination of interferon ${\alpha}$-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy. Antiviral Res. 55, 425-435   DOI   ScienceOn
36 Jen, J., M. Laughlin, C. Chung, S. Heft, M.B. Affrime, S.K. Gupta, P. Glue, and G. Hajian. 2002. Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic-pharmacodynamic models. Clin. Pharmacol. Therapeutics 72, 349-361   DOI   ScienceOn
37 Durantel, D., N. Branza-Nichita, S. Carrouee-Durantel, T.D. Butters, R.A. Dwek, and N. Zitzmann. 2001. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J. Virol. 75, 8987-8998   DOI   ScienceOn
38 Jassim, S.A.A. and M.A. Naji. 2003. Novel antiviral agents: a medicinal plant perspective. J. Appl. Micro. 95, 412-427   DOI   ScienceOn
39 Look, M.P., A. Gerard, G.S. Rao, T. Sudhop, H.P. Fischer, T. Sauerbruch, and U. Spengler. 1999. Interferon/antioxidant combination therapy for chronic hepatitis C-a controlled pilot trial. Antiviral Res. 43, 113-122   DOI   ScienceOn
40 Jacob, J.R., R.H. Liu, C. Roneker, F. Noronha, J.H. Hotchkiss, and B.C. Tennant. 1994. Characterization and immortalization of woodchuck hepatocytes isolated from normal and hepadnavirus infected woodchucks (Marmota monax). Exp. Cell Res. 212, 42-48   DOI   ScienceOn
41 Cavalletto, L., L. Chemello, C. Donada, P. Casarin, F. Belussi, E. Bernardinello, F. Marino, P. Pontisso, A. Gatta, and A. Alberti. 2000. The pattern of response to interferon alpha predicts sustained response to a 6-month alpha-INF and ribavirin retreatment for chronic hepatitis C. J. Hepatol. 33, 128-134   DOI   ScienceOn
42 McHutchison, J.G., S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, Z.D. Goodman, M.H. Ling, S. Cort, and J.K. Albrecht. 1998. Interferon alpha 2a alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England J. Med. 339, 1485-1492   DOI   ScienceOn
43 Di Bisceglie, A.M. and B.R. Bacon. 1999. The unmet challenges of hepatitis C. Scientific American 281, 80-85   PUBMED
44 Block, T.M., X. Lu, F.M. Platt, G.R. Foster, W.H. Gerlich, B.S. Blumber, and R.A. Dwek. 1994. Secretion of hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. USA 91, 2235-2239
45 Seeff, L.B., K.L. Lindsay, B.R. Bacon, T.F. Kresina, and J.H. Hoofnagle. 2001. Complementary and alternative medicine in chronic liver disease. Hepatology 34, 595-603   DOI   ScienceOn
46 Jarvis, B. and D. Faulds. 1999. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 58, 101-141   DOI   ScienceOn
47 Block, T.M., X. Lu, A.S. Mehta, B.S. Blumberg, B.C. Tennant, M. Ebling, B. Korba, D.M. Lansky, G.S. Jacob, and R.A. Dwek. 1998. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nature Med. 4, 610-614   DOI   ScienceOn
48 Wu, S.F., C.J. Lee, C.L. Liao, R.A. Dwek, N. Zitzmann, and Y.L. Lin. 2002. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 67, 3596-3604